NCT03017690已完成不适用
Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Ipsen
- 入组人数
- 22
- 试验地点
- 5
- 主要终点
- The total time for product preparation and administration
研究概览
简要总结
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women must be 18 years of age or older
- •A current diagnosis of advanced, unresectable GEP-NET
- •Provided written informed consent to participate in the study
- •Currently receiving lanreotide or octreotide LAR and has received at least one prior injection of current somatostatin analogues (SSA).
排除标准
- •Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial
- •Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate more than 1 injection on the same day
- •Scheduled to receive any other treatment in the infusion center/room on the same day and as part of the same appointment
- •Known hypersensitivity to somatostatin analogues
结局指标
主要结局
The total time for product preparation and administration
时间窗: Day 1
Total drug delivery time
次要结局
- Number of clogging episodes(Day 1)
- Patient satisfaction(Day 1)
- Healthcare resource utilization(Day 1)
- Total patient wait time for administration(Day 1)
- Pharmacist and/or nurse satisfaction and product preference(Day 1 and at the end of the study (approximately 3 months))
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyAcromegalyNCT00600886Novartis Pharmaceuticals358
进行中（未招募）
2 期
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)ParagangliomaPheochromocytomaNCT03946527Antonio Fojo10
已完成
不适用
Somatuline Predictive Factors in Acromegaly and NETNeuroendocrine TumoursAcromegalyNCT01840449Ipsen156
Unknown
4 期
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NETNeuroendocrine TumorsNCT03083210Samsung Medical Center28
已完成
不适用
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)Non-Small Cell Lung CancerNCT02679170Pfizer692